Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

March 31, 2017

Conditions
Patients Undergoing Allogeneic Stem Cell Transplantation
Interventions
BIOLOGICAL

CMV/EBV specific T-cell

Peptide stimulated allogeneic T-cells with dual specificity for CMV and EBV

Trial Locations (6)

13353

Charité University Hospital Berlin, Berlin

55131

University of Mainz, Mainz

81377

University of Munich LMU, Munich

86156

Medical Center Augsburg, Augsburg

91054

Universitiy Hospital Erlangen, Erlangen

93053

University of Regensburg, Regensburg

Sponsors
All Listed Sponsors
collaborator

Ludwig-Maximilians - University of Munich

OTHER

collaborator

University of Regensburg

OTHER

collaborator

Johannes Gutenberg University Mainz

OTHER

collaborator

Charite University, Berlin, Germany

OTHER

collaborator

University Hospital Augsburg

OTHER

collaborator

BayImmuNet Bavarian Immunotherapy Network

UNKNOWN

collaborator

German Research Foundation

OTHER

lead

University of Erlangen-Nürnberg Medical School

OTHER